Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. more
Time Frame | KPRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.73% | -0.33% | -1.49% |
1-Month Return | -0.9% | -4.57% | -0.37% |
3-Month Return | -4.36% | -9.96% | 3.89% |
6-Month Return | -19.36% | -5.67% | 9.34% |
1-Year Return | -34.13% | 2.53% | 25.19% |
3-Year Return | -98.98% | -1.43% | 24.7% |
5-Year Return | -99.89% | 34.73% | 85.39% |
10-Year Return | -99.99% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.69M | 12.06K | 12.06K | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.45,"profit":true},{"date":"2021-12-31","value":0.45,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 4.89K | 200.22K | 227.27K | 134.03K | 4.03M | [{"date":"2019-12-31","value":0.12,"profit":true},{"date":"2020-12-31","value":4.97,"profit":true},{"date":"2021-12-31","value":5.64,"profit":true},{"date":"2022-12-31","value":3.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 2.68M | (188.16K) | (227.27K) | (134.03K) | (4.03M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7.02,"profit":false},{"date":"2021-12-31","value":-8.48,"profit":false},{"date":"2022-12-31","value":-5,"profit":false},{"date":"2023-12-31","value":-150.2,"profit":false}] |
Gross Margin | 99.82% | (1560.34%) | (1884.68%) | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-1563.19,"profit":false},{"date":"2021-12-31","value":-1888.11,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 9.80M | 8.22M | 10.67M | 11.73M | 12.59M | [{"date":"2019-12-31","value":77.82,"profit":true},{"date":"2020-12-31","value":65.34,"profit":true},{"date":"2021-12-31","value":84.8,"profit":true},{"date":"2022-12-31","value":93.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (7.00M) | (8.19M) | (16.94M) | (12.31M) | (12.59M) | [{"date":"2019-12-31","value":-700097500,"profit":false},{"date":"2020-12-31","value":-818941600,"profit":false},{"date":"2021-12-31","value":-1694246100,"profit":false},{"date":"2022-12-31","value":-1230952300,"profit":false},{"date":"2023-12-31","value":-1258689600,"profit":false}] |
Total Non-Operating Income/Expense | 107.42K | 38.31K | 266.77K | (1.34M) | 330.76K | [{"date":"2019-12-31","value":32.48,"profit":true},{"date":"2020-12-31","value":11.58,"profit":true},{"date":"2021-12-31","value":80.65,"profit":true},{"date":"2022-12-31","value":-404.77,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (7.00M) | (8.08M) | (16.70M) | (13.70M) | (12.42M) | [{"date":"2019-12-31","value":-700130000,"profit":false},{"date":"2020-12-31","value":-807988500,"profit":false},{"date":"2021-12-31","value":-1669970000,"profit":false},{"date":"2022-12-31","value":-1369662000,"profit":false},{"date":"2023-12-31","value":-1242357700,"profit":false}] |
Income Taxes | 95.40K | 12.05K | (304.78K) | (113.01K) | 90.32K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":12.64,"profit":true},{"date":"2021-12-31","value":-319.49,"profit":false},{"date":"2022-12-31","value":-118.46,"profit":false},{"date":"2023-12-31","value":94.68,"profit":true}] |
Income After Taxes | (7.10M) | (8.09M) | (16.39M) | (13.58M) | (12.51M) | [{"date":"2019-12-31","value":-709669600,"profit":false},{"date":"2020-12-31","value":-809194000,"profit":false},{"date":"2021-12-31","value":-1639491900,"profit":false},{"date":"2022-12-31","value":-1358361000,"profit":false},{"date":"2023-12-31","value":-1251389600,"profit":false}] |
Income From Continuous Operations | (7.10M) | (8.09M) | (16.39M) | (13.58M) | (12.74M) | [{"date":"2019-12-31","value":-709669600,"profit":false},{"date":"2020-12-31","value":-809194000,"profit":false},{"date":"2021-12-31","value":-1639491900,"profit":false},{"date":"2022-12-31","value":-1358361000,"profit":false},{"date":"2023-12-31","value":-1274373600,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.10M) | (8.09M) | (16.39M) | (13.58M) | (12.51M) | [{"date":"2019-12-31","value":-709669600,"profit":false},{"date":"2020-12-31","value":-809194000,"profit":false},{"date":"2021-12-31","value":-1639491900,"profit":false},{"date":"2022-12-31","value":-1358361000,"profit":false},{"date":"2023-12-31","value":-1251389600,"profit":false}] |
EPS (Diluted) | (47.75) | (54.03) | (41.06) | (41.46) | (3.15) | [{"date":"2019-12-31","value":-4775,"profit":false},{"date":"2020-12-31","value":-5403,"profit":false},{"date":"2021-12-31","value":-4106,"profit":false},{"date":"2022-12-31","value":-4146,"profit":false},{"date":"2023-12-31","value":-315,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KPRX | |
---|---|
Cash Ratio | 8.23 |
Current Ratio | 8.97 |
Quick Ratio | 9.06 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KPRX | |
---|---|
ROA (LTM) | 12.96% |
ROE (LTM) | 13.69% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KPRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KPRX | |
---|---|
Trailing PE | 0.22 |
Forward PE | 2.41 |
P/S (TTM) | 0.62 |
P/B | 0.33 |
Price/FCF | 12 |
EV/R | 569.41 |
EV/Ebitda | NM |
Kiora Pharmaceuticals Inc (KPRX) share price today is $3.29
Yes, Indians can buy shares of Kiora Pharmaceuticals Inc (KPRX) on Vested. To buy Kiora Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KPRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kiora Pharmaceuticals Inc (KPRX) via the Vested app. You can start investing in Kiora Pharmaceuticals Inc (KPRX) with a minimum investment of $1.
You can invest in shares of Kiora Pharmaceuticals Inc (KPRX) via Vested in three simple steps:
The 52-week high price of Kiora Pharmaceuticals Inc (KPRX) is $8.98. The 52-week low price of Kiora Pharmaceuticals Inc (KPRX) is $3.
The price-to-earnings (P/E) ratio of Kiora Pharmaceuticals Inc (KPRX) is 0.219
The price-to-book (P/B) ratio of Kiora Pharmaceuticals Inc (KPRX) is 0.33
The dividend yield of Kiora Pharmaceuticals Inc (KPRX) is 0.00%
The market capitalization of Kiora Pharmaceuticals Inc (KPRX) is $10.75M
The stock symbol (or ticker) of Kiora Pharmaceuticals Inc is KPRX